Murray Stahl's ALLO Position Overview
Murray Stahl (via Horizon Kinetics Asset Management LLC) currently holds 18,388 shares of Allogene Therapeutics, Inc. (ALLO) worth $25,191, representing 0.00% of the portfolio. First purchased in 2023-Q1, this medium-term investment has been held for 12 quarters.
Based on 13F filings, Murray Stahl has maintained a strategic position in ALLO, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 806 shares. Largest reduction occurred in Q4 2023, reducing 806 shares.
Analysis based on 13F filings available since 2013 Q2
Murray Stahl's Allogene Therapeutics (ALLO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Allogene Therapeutics (ALLO) Trades by Murray Stahl
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -806 | Reduce 4.20% | 18,388 | $1.37 |
| Q3 2025 | +806 | Add 4.38% | 19,194 | $1.24 |
| Q2 2025 | -806 | Reduce 4.20% | 18,388 | $1.13 |
| Q4 2024 | +806 | Add 4.38% | 19,194 | $2.13 |
| Q3 2024 | -806 | Reduce 4.20% | 18,388 | $2.80 |
| Q4 2023 | -806 | Reduce 4.03% | 19,194 | $3.21 |
| Q1 2023 | +20,000 | New Buy | 20,000 | $4.94 |
Murray Stahl's Allogene Therapeutics Investment FAQs
Murray Stahl first purchased Allogene Therapeutics, Inc. (ALLO) in Q1 2023, acquiring 20,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl has held Allogene Therapeutics, Inc. (ALLO) for 12 quarters since Q1 2023.
Murray Stahl's largest addition to Allogene Therapeutics, Inc. (ALLO) was in Q1 2023, adding 20,000 shares worth $98,800.
According to the latest 13F filing for Q4 2025, Murray Stahl's firm, Horizon Kinetics Asset Management LLC, owns 18,388 shares of Allogene Therapeutics, Inc. (ALLO), valued at approximately $25,191.
As of the Q4 2025 filing, Allogene Therapeutics, Inc. (ALLO) represents approximately 0.00% of Murray Stahl's publicly disclosed stock portfolio, making it one of their key holdings.
Murray Stahl's peak holding in Allogene Therapeutics, Inc. (ALLO) was 20,000 shares, as reported at the end of Q1 2023.